Pfizer (PFE) ended the recent trading session at $28.22, demonstrating a +0.75% swing from the preceding day's closing price. This move outpaced the S&P 500's daily loss of 0.19%. Elsewhere, the Dow saw an upswing of 0.1%, while the tech-heavy Nasdaq depreciated by 0.54%.The drugmaker's stock has climbed by 3.86% in the past month, exceeding the Medical sector's gain of 2.91% and the S&P 500's gain of 3.18%.Market participants will be closely following the financial results of Pfizer in its upcoming release ...

Pfizer (PFE) announced positive overall survival data from a phase III study of Adcetris regimen in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) irrespective of CD30 expression.The ECHELON-3 study, evaluating Adcetris in combination with lenalidomide and rituximab, demonstrated a notable improvement in the primary endpoint of overall survival compared to the standard lenalidomide and rituximab plus placebo regimen. Moreover, secondary endpoints such as progression-free survival an ...

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced that the European Commission (EC) has granted marketing authorization for the company’s 20-valent pneumococcal conjugate vaccine, marketed in the European Union under the brand name PREVENAR 20®, for active immunization for the prevention of invasive disease, pneumonia and acute otitis media caused by Streptococcus pneumoniae in infants, children and adolescents from 6 weeks to less than 18 years of age. “The EC’s authorization of PREVENA ...

Pfizer Inc. (NYSE:PFE) Leerink Partners Global Biopharma Conference 2024 Call March 12, 2024 8:00 AM ET Company Participants Ronen Tamir - Vice President, Investor Relations Mikael Dolsten - Chief Scientific Officer & President, Pfizer Research and Development Conference Call Participants David Risinger - Leerink Partners David Risinger Good morning, everybody. So it's very much my pleasure to start off the day today with Pfizer's Head of R&D, Mikael Dolsten. It's very much my pleasure to welcome him. And R ...

ToplinePfizer’s cancer drug Adcetris extended survival in patients with a common form of lymphoma in a late-stage trial, the company announced Tuesday, supporting Pfizer’s efforts to expand into cancer treatments amid declining Covid vaccine sales.The drugmaker invested in cancer drugs last year amid declining Covid vaccine sales. Getty Images Key FactsPatients with diffuse large B-cell lymphoma showed a “statistically significant and clinically meaningful improvement” in overall survival—the amount of time ...

Michael M. SantiagoIntroduction On December 21, 2023, I wrote about Pfizer Inc. (NYSE:PFE) stock for the first time after a long hiatus since initiating coverage in November 2021. Last time, I wrote about PFE appearing oversold and undervalued due to likely underestimated EPS forecasts for FY 2025 and beyond. I urged not to panic, but to think about building a long position at the low price levels. Unfortunately, the PFE stock has since significantly underperformed the broader market: Seeking Alpha, my ...

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced that a Phase 3 study of the antibody-drug conjugate ADCETRIS® (brentuximab vedotin) in combination with lenalidomide and rituximab for the treatment of patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) showed a statistically significant and clinically meaningful improvement in overall survival (OS) compared to lenalidomide and rituximab plus placebo. Positive outcomes were also observed in key secondary endpoints, inclu ...

Pfizer is pushing to be more involved in cancer drugs after a turbulent year marked by the rapid decline of its COVID business.During a four-hour investor event last week, Pfizer pushed its initative to “accelerate breakthroughs that help people with cancer globally live better and longer lives,” according to CNBC.The drugmaker has ramped up its efforts to “outdo cancer” since it acquired oncology biotech firm Seagen for $43 billion in December.The acquisition doubled Pfizer’s cancer drug pipeline to 60 dif ...

Dividend stocks are great for several reasons. Some use the regular payouts they offer to complement their income, whether in retirement or otherwise, while others reinvest the money to boost long-term returns. Dividend stocks have generally outperformed their non-dividend-paying peers over long periods.Clearly, this mode of investing has advantages, but if there's one thing better than investing in dividend stocks, it's investing in cheap dividend stocks. Let's consider two companies that fit the bill: Pfi ...

Sometimes quality companies that have fallen on hard times can make for great investments. The market usually sells off their stocks to levels more than warranted when the underlying business hits a lean patch, or fails to meet the market's baked-in expectations, over the short term. But if the long-term prospects are fundamentally intact, such market actions merely make the stocks cheap, making them ripe pickings for value investors. However, it's also true that many investors have lost their shirts by bet ...